Orris

What are different phases of organophosphorus poisonings

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from the textbooks. Here is the detailed answer:

Phases / Clinical Syndromes of Organophosphorus (OP) Poisoning

OP compounds inhibit acetylcholinesterase by phosphorylation, causing acetylcholine accumulation at synapses and neuromuscular junctions. Four well-defined clinical syndromes follow OP exposure, as described in Tintinalli's Emergency Medicine and Bradley and Daroff's Neurology.

Phase 1: Acute Cholinergic Crisis

Timing: Within minutes to 24 hours of exposure (most symptomatic within 8 hours; nearly all within 24 hours)
This is the classic "cholinergic toxidrome" resulting from excess acetylcholine at muscarinic, nicotinic, and CNS receptors.
Muscarinic effects (mnemonic: SLUDGE / DUMBELS / "Killer Bs"):
  • Salivation, Lacrimation, Urinary incontinence, Defecation, GI cramps, Emesis (SLUDGE)
  • Bradycardia, Bronchorrhea, Bronchospasm - the "Killer Bs" - these cause most deaths
  • Miosis
Nicotinic effects (at neuromuscular junctions and sympathetic ganglia):
  • Muscle fasciculations, cramps, weakness
  • Diaphragm and respiratory muscle weakness - can lead to respiratory failure
  • Tachycardia, hypertension, mydriasis, pallor (sympathetic ganglia stimulation)
  • In severe poisoning, nicotinic features may appear first
CNS effects:
  • Anxiety, restlessness, emotional lability
  • Tremor, confusion, delirium, hallucinations
  • Seizures, coma
Death in this phase is typically from respiratory failure due to bronchorrhea combined with respiratory muscle paralysis.

Phase 2: Intermediate Syndrome (IMS)

Timing: 1-5 days after acute exposure (typically 24-96 hours after the cholinergic crisis resolves)
The IMS occurs in up to 40% of patients following ingestion. It reflects prolonged nicotinic receptor stimulation from persistent acetylcholinesterase inhibition.
Key features:
  • Paralysis of proximal limb muscles, neck flexor muscles, cranial nerve-innervated muscles
  • Respiratory muscle paralysis - patients may require mechanical ventilation
  • Notably, signs of cholinergic excess are absent at this stage
  • EMG may assist in diagnosis
  • Resolves in approximately 7 days with supportive care
Aggressive early antidote therapy (atropine + pralidoxime) during the acute phase may prevent or reduce the severity of IMS.
IMS has not been reported after chemical warfare nerve agent (nerve gas) poisoning - only after pesticide exposures.

Phase 3: Organophosphate-Induced Delayed Neuropathy (OPIDN)

Timing: 2-5 weeks after acute exposure
Not all OP compounds cause this - it occurs only with specific agents (e.g., tri-ortho cresyl phosphate, leptophos, trichlorfon, mipafox). It is caused by phosphorylation and "aging" of neuropathy target esterase (NTE), not acetylcholinesterase.
Key features:
  • Paresthesias and cramps in the feet and calves initially
  • Progressive distal-to-proximal weakness - can lead to quadriplegia in severe cases
  • Maximum deficit develops within ~2 weeks after onset
  • Sensory complaints are often inconspicuous despite motor involvement
  • The pattern can mimic Guillain-Barre syndrome
  • No specific preventive treatment exists; management is supportive
Cognitive dysfunction, impaired memory, mood changes, autonomic dysfunction, and extrapyramidal signs can also be components of OPIDN.

Phase 4: Chronic Toxicity

Timing: Gradual onset with repeated low-level exposure (not a single acute exposure)
Seen primarily in agricultural workers with daily occupational exposure.
Key features:
  • Symmetrical sensorimotor axonopathy
  • Symptoms are often non-specific - "dippers' flu" presentation (headache, rhinitis, myalgia, flu-like symptoms)
  • No clear cholinergic syndrome
  • Neuropsychological effects: impaired neurobehavioral function (supported by meta-analyses of well-designed studies)
  • Chronic fatigue syndrome and multiple chemical sensitivity have been reported at very low doses, particularly in women

Summary Table

PhaseTimingMechanismKey Features
1. Acute Cholinergic CrisisMinutes-24 hrsAChE inhibition → ACh excessSLUDGE, Killer Bs, fasciculations, seizures, coma
2. Intermediate Syndrome (IMS)1-5 daysPersistent nicotinic receptor stimulationProximal muscle paralysis, respiratory failure, no cholinergic signs
3. Delayed Neuropathy (OPIDN)2-5 weeksNTE inhibition + "aging"Distal-to-proximal neuropathy, weakness, GBS-like
4. Chronic ToxicityRepeated exposure (weeks-months)Cumulative cholinesterase suppressionNon-specific symptoms, sensorimotor axonopathy, neurobehavioral changes
Treatment highlights:
  • Atropine - reverses muscarinic effects (does NOT reverse nicotinic/neuromuscular effects)
  • Pralidoxime (2-PAM) - reactivates AChE if given before "aging" occurs; more effective in early treatment
  • Benzodiazepines - for seizures
  • Airway/ventilation - the most critical priority; succinylcholine has prolonged effect in OP poisoning (use rocuronium instead for intubation)
Sources: Tintinalli's Emergency Medicine, pp. 1342-1343 | Bradley and Daroff's Neurology in Clinical Practice, pp. 1812-1813 | Rosen's Emergency Medicine, p. 1511
This is a shared conversation. Sign in to Orris to start your own chat.